Home › Non-Small Cell Lung Cancer › Massachusetts
Non-Small Cell Lung Cancer clinical trials in Massachusetts
99 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
- Boston87 studies
- Worcester14 studies
- Somerville7 studies
- Newton5 studies
- Springfield4 studies
- Lynn4 studies
- Lawrence3 studies
- Quincy3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07111520Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07100080This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Southcoast Centers for Cancer Care, Fairhaven
- Southcoast Centers for Cancer Care, Fall River
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beverly Hospital, Beverly
- Lahey Clinic, Burlington
- Addison Gilbert Hospital, Gloucester
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beverly Hospital, Beverly
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- and 8 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- University of Massachusetts Memorial Medical Center, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06472245A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Massachusetts General Hospital - Neurology, Boston
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06914128A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07291037A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Massachusetts General Hospital ( Site 0136), Boston
- Dana Farber Cancer Hospital ( Site 0155), Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06623422A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07541170A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
RecruitingPhase 1
Ages 18 to 99 · All sexes · Updated Nov 6, 2026 · NCT06983743A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- University of Massachusetts Worcester, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07144280A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute - Chestnut Hill, Newton
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Massachusetts General Hospital, Boston
- University of Massachusetts Memorial Medical Center, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Local Institution - 0603, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07361497A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Lahey Hospital & Medical Center, Burlington
- Reliant Medical Group, Worcester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06890598A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150664A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06706076Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT03191149A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07542704A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Boston Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT05498428FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
- Dana Farber Cancer Institute (DFCI), Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06303505A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06667908A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06720987Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07195695Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton
- Brigham and Womens/Mass General Health Care Center at Foxborough, Foxborough
- and 3 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT04613596Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT05098132A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06357533Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07751042Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Dana-Farber Cancer Institute /ID# 278417, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06772623A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06875310A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06835569Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT06899126From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.